Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
NCT06202599
·
clinicaltrials.gov ↗
COMPLETED
Status
124
Enrollment
OTHER
Sponsor class
Conditions
Bone Sarcoma
Soft Tissue Sarcoma
Refractory Tumor
Interventions
DRUG:
Fruquintinib
Sponsor
Peking University People's Hospital